Drugs / AZD1236
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01007929 | Oct → Nov 2009 | — | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00767052 | Sep → Dec 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00812045 | Dec 2009 → Aug 2010 | cystic fibrosis | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 2 | NCT00758459 | Sep 2008 → Mar 2009 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00758706 | Sep 2008 → May 2009 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD1236 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00758459 ↗ |
| Action | Inhibit | “Matrix metalloproteinase 12 inhibitor” CHEMBL4297352 ↗1“Matrix metalloproteinase 9 inhibitor” CHEMBL4297352 ↗ |
| Modality | Small molecule | — CHEMBL4297352 ↗ |
| Route | Oral | “oral tablet” NCT00758459 ↗ |
| Target | MMP12 | “Matrix metalloproteinase 12 inhibitor” CHEMBL4297352 ↗ |
| Target | MMP9 | “Matrix metalloproteinase 9 inhibitor” CHEMBL4297352 ↗ |